Opus Genetics, Inc. (IRD) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. The registrant, formerly known as Ocuphire Pharma, Inc., completed the acquisition of Opus Genetics, Inc. ("Former Opus") on October 22, 2024, subsequent to the reporting period. The financial statements presented reflect the historical operations of Ocuphire Pharma prior to this merger. The company is a clinical-stage ophthalmic biotechnology firm developing gene therapies for inherited retinal diseases (IRDs) and small-molecule treatments. Its primary revenue source is a collaboration agreement with Viatris, Inc. regarding the product RYZUMVI (Phentolamine Ophthalmic Solution 0.75%).
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $3,867 | $11,935 | $6,690 | $17,358 |
| Net Loss | $(7,526) | $5,561 (Income) | $(22,397) | $(5,191) |
| Operating Expenses | $11,876 | $5,549 | $30,735 | $22,492 |
| Cash & Equivalents (Sep 30) | $36,632 | $42,350 | $36,632 | $42,350 |
| Accumulated Deficit | $(103,863) | $(76,671) | $(103,863) | $(76,671) |
| Net Cash Used in Operating Activities | N/A | N/A | $(18,138) | $(5,660) |
Note: Revenue consists primarily of reimbursements for research and development services and royalties from the Viatris License Agreement. There were no product sales revenues recorded directly by the company.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 68% in Q3 2024 compared to Q3 2023. This is primarily due to the recognition of a one-time $10 million milestone payment in Q3 2023 following FDA approval of RYZUMVI, which did not recur in the current period.
- Increased Operating Loss: The company reported a net loss of $7.5 million in Q3 2024, compared to net income of $5.6 million in Q3 2023. The shift to a loss was driven by the absence of the milestone revenue and a 114% increase in operating expenses.
- R&D Expense Surge: Research and development expenses increased to $9.0 million in Q3 2024 from $3.5 million in Q3 2023. This increase is attributed to higher clinical costs for the Lynx-2 and Vega-3 trials, drug manufacturing costs, and toxicology services related to the APX3330 program.
- Liquidity Position: Cash and cash equivalents decreased by approximately $13.9 million during the nine months ended September 30, 2024, resulting in a cash balance of $36.6 million. Management believes this is sufficient to fund operations for at least 12 months.
Guidance, Outlook, and Risks
- Strategic Pivot: Following the Opus Acquisition, the company is redirecting resources toward its acquired gene therapy programs (OPGx-LCA5 and OPGx-BEST1). The company intends to seek a strategic partner to advance the APX3330 diabetic retinopathy program rather than developing it internally.
- Clinical Milestones:
- OPGx-LCA5: Phase 1/2 trial showed visual improvement in 3/3 adult patients. Pediatric enrollment expected in Q1 2025; first data anticipated in Q3 2025.
- RYZUMVI/PS: VEGA-3 Phase 3 trial for presbyopia is underway with data expected in H1 2025. LYNX-2 Phase 3 trial for mesopic vision disturbances continues enrollment with data expected in Q1 2025.
- Capital Requirements: The company expects to continue incurring losses and will require additional capital to fund development. It maintains an At-The-Market (ATM) program and an equity line of credit with Lincoln Park Capital Fund (up to $50 million).
- Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to secure a partner for APX3330, integration challenges from the Opus Acquisition, and the potential dilution from future equity financings. The company also faces risks related to the Series A Preferred Stock issued in the merger, which may require cash dividends if not converted by stockholders in 2025.
Investor Verification Checklist
- Merger Accounting: Verify the final purchase price allocation and pro forma financial impact of the Opus Acquisition, as purchase accounting was incomplete at the time of filing.
- APX3330 Partnership: Monitor announcements regarding the strategic partnership for the APX3330 program, as internal development is being paused to preserve cash.
- Cash Burn Rate: Track the monthly cash burn rate against the $36.6 million cash balance to assess the runway for the new gene therapy pipeline.
- Series A Preferred Stock: Review the terms of the Series A Preferred Stock issued to Former Opus shareholders, specifically the dividend obligations ($26.00/share quarterly) if conversion is not approved at the 2025 Annual Meeting.
- Viatris Royalties: Monitor sales data for RYZUMVI to estimate future royalty revenue streams, which are currently minimal.